Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91

Benzinga Newsdesk www.benzinga.com Negative 93.2%

Neg 93.2% Neu 0% Pos 0%

Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ:VERA) with a Outperform and lowers the price target from $95 to $91.